

Table 2bis. Hazard ratios of invasive breast cancer for EP-MHT use compared with MHT never-use.

	Ever use of EP-MHT		Recent use of EP-MHT		Past use of EP-MHT	
	No. of cases*	Hazard ratio (95% CI)†	No. of cases	Hazard ratio (95% CI)†	No. of cases	Hazard ratio (95% CI)†
<b>Gap time</b>						
≤ 1 year	660	1.56 (1.38-1.76)	586	1.63 (1.43-1.84)	64	1.16 (0.89-1.51)
1-3 years	225	1.45 (1.24-1.71)	200	1.54 (1.30-1.82)	21	0.91 (0.59-1.41)
3-5 years	68	1.20 (0.93-1.55)	61	1.33 (1.02-1.74)	7	0.69 (0.33-1.46)
> 5 years	114	1.37 (1.12-1.69)	90	1.37 (1.09-1.72)	21	1.24 (0.80-1.93)

Abbreviations: EP-MHT, estrogen-progestagen menopausal hormone therapy; CI, confidence interval

\* 17 cases were diagnosed among women for whom recency of use was not known; 567 cases were further diagnosed among MHT never-users; and 92 among women with a missing MHT exposure status

† Adjusted for: age (time scale) and age at menopause (continuous). Further stratified on year of birth ([1925-1930]/[1930-1935]/[1935-1940]/[1940-1945]/[1945-1950])

Table 3bis. Hazard ratios of invasive breast cancer for EP-MHT recent use, according to gap time, type of progestagen and total duration of use, compared with MHT never-use. E3N study 1992-2005.

	Total duration of EP-MHT use								<i>P for trend with duration of use</i>
	≤2 years		]2-5] years		]5-10] years		>10 years		
	No. of cases	Hazard ratio* (95% CI)	No. of cases	Hazard ratio* (95% CI)	No. of cases	Hazard ratio* (95% CI)	No. of cases	Hazard ratio* (95% CI)	
<b>Recent use of any type of EP-MHT</b>									
Gap time ≤ 1 year	133	1.61 (1.30-1.98)	163	1.45 (1.20-1.74)	196	1.64 (1.38-1.95)	94	1.91 (1.51-2.41)	0.10
Gap time 1-3 years	45	1.38 (1.01-1.89)	66	1.60 (1.23-2.08)	64	1.48 (1.13-1.93)	25	1.83 (1.22-2.76)	0.46
Gap time 3-5 years	10	0.94 (0.50-1.77)	19	1.36 (0.86-2.16)	25	1.56 (1.04-2.34)	7	1.41 (0.67-3.00)	0.36
Gap time > 5 years	17	1.03 (0.64-1.68)	33	1.63 (1.14-2.33)	35	1.61 (1.13-2.29)	5	0.90 (0.37-2.19)	0.81
<b>Recent use of estrogen + progesterone</b>									
Gap time ≤ 1 year	17	0.95 (0.58-1.55)	27	0.99 (0.67-1.47)	55	1.67 (1.23-2.25)	31	1.93 (1.31-2.85)	0.004
Gap time 1-3 years	6	0.69 (0.31-1.55)	12	1.02 (0.57-1.82)	12	0.93 (0.52-1.66)	8	1.77 (0.87-3.60)	0.28
Gap time 3-5 years	2	0.64 (0.16-2.58)	6	1.37 (0.61-3.07)	5	0.92 (0.38-2.23)	3	1.62 (0.52-5.10)	0.40
Gap time > 5 years	6	1.04 (0.46-2.32)	12	1.65 (0.93-2.92)	7	0.86 (0.41-1.82)	1	0.43 (0.06-3.10)	0.14
<b>Recent use of estrogen + dydrogesterone</b>									
Gap time ≤ 1 year	22	1.40 (0.90-2.16)	24	1.14 (0.75-1.74)	30	1.42 (0.97-2.08)	11	1.18 (0.64-2.18)	0.88
Gap time 1-3 years	9	1.54 (0.79-2.99)	10	1.36 (0.72-2.54)	10	1.23 (0.65-2.31)	5	1.87 (0.77-4.56)	0.98
Gap time 3-5 years	2	0.93 (0.23-3.71)	4	1.61 (0.60-4.31)	4	1.28 (0.48-3.43)	2	1.71 (0.43-6.90)	0.86
Gap time > 5 years	4	1.29 (0.48-3.45)	2	0.52 (0.13-2.09)	9	2.12 (1.09-4.12)	2	1.92 (0.48-7.77)	0.59
<b>Recent use of estrogen + other progestagen</b>									
Gap time ≤ 1 year	94	1.96 (1.55-2.49)	112	1.81 (1.46-2.24)	111	1.82 (1.46-2.25)	52	2.37 (1.76-3.20)	0.25
Gap time 1-3 years	30	1.70 (1.17-2.47)	44	2.07 (1.51-2.83)	42	1.99 (1.44-2.74)	12	2.04 (1.14-3.65)	0.42
Gap time 3-5 years	6	1.15 (0.51-2.58)	9	1.32 (0.68-2.56)	16	2.27 (1.37-3.75)	2	1.14 (0.28-4.57)	0.43
Gap time > 5 years	7	0.94 (0.44-1.98)	19	2.15 (1.35-3.40)	19	2.15 (1.35-3.42)	2	0.99 (0.25-4.01)	0.43

Abbreviations: EP-MHT, estrogen-progestagen menopausal hormone therapy; CI, confidence interval

\* Adjusted for the same covariates as in Table 2bis. In analyses according to type of recent EP-MHT, models are additionally adjusted for past use of estrogen combined with progesterone, estrogen combined with dydrogesterone, estrogen combined with other progestagens